An interventional study of AI-assisted decision-making in Rectal Cancer, sponsored by Peking Union Medical College Hospital. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-12.
Sponsored by Peking Union Medical College Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Rectal Neoplasms by Peking Union Medical College Hospital — 9 open to participants now, 10 under way, none of them phase 3. Rectal Neoplasms · Peking Union Medical College Hospital.
Among the 13 studies in Rectal Neoplasms by Peking Union Medical College Hospital, this one is the 8th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2026, is one of 7 with no phase, and was the 12th registered.
2,403 studies on the registry are indexed under Rectal Neoplasms; 587 are open to participants now.
Browse Rectal Neoplasms studies →9 of the 13 studies in Rectal Neoplasms by Peking Union Medical College Hospital are open now, in 1 country. Recruiting first, the newest first:
Peking Union Medical College Hospital · Sites in China
Ages 18+
Peking Union Medical College Hospital · Sites in China
Ages 18–75
Peking Union Medical College Hospital · Sites in China
Peking Union Medical College Hospital · Sites in China
Ages 18–100
Peking Union Medical College Hospital · Sites in China
Ages 18–75
By country, each count listing its studies:
Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 1
First in 2017; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 68 is close to the median of 65 across 1,753 interventional studies indexed under Rectal Neoplasms.
Median enrollment 150 across the 11 interventional studies, 1,970 across the 2 observational. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
Peking Union Medical College Hospital is the lead sponsor of 1,158 studies on the registry; 477 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
4 of the studies in Rectal Neoplasms by Peking Union Medical College Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07108127Peking Union Medical College HospitalEfficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer | 2026-12-01 |
| NCT06194708Peking Union Medical College HospitalReasons for Non-reversal of Temporary Stomas After Surgeries of Mid-low Rectal Cancer (NORESTO Study) | 2027-01-01 |
| NCT05871762Peking Union Medical College HospitalChoice of the Optimal Treatment Strategies for Mid-low REctal Cancer | 2027-05-17 |
| NCT07761169Peking Union Medical College HospitalRandomized Controlled Trial of the SurgDiff Model for Predicting Surgical Difficulty to Help Choose Approach in Mid-Low Rectal Cancer | 2027-09-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 13 studies in Rectal Neoplasms by Peking Union Medical College Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to investigate the feasibility of utilizing the SurgDiff surgical difficulty prediction model to assist surgeons in formulating precise surgical plans.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The SurgDiff model performs a difficulty assessment based on the patient's preoperative MRI scans and clinical data, thereby assisting the surgeon in formulating the surgical plan.
Procedure: AI-assisted decision-making
The surgeon selects the surgical approach and performs the procedure
The SurgDiff model performs a difficulty assessment based on the patient's preoperative MRI scans and clinical data, thereby assisting the surgeon in formulating the surgical plan
Mesorectal incomplete rate
Time frame: 2 weeks after surgery
Operative conversion rate
Defined as the proportion of cases where laparoscopic total mesoresection (laTME) was converted to open total mesoresection (taTME), or where taTME was converted back to laTME, or where conversion occurred to an open surgical approach during the procedure.
Time frame: during the surgery
Positive resection margin rate
defined as the presence of cancer cells on the distal rectal resection margin
Time frame: 2 weeks after surgery
No study locations are listed for this record.
Start is estimated for Aug 2026; primary completion for Sep 2027, 12 months later.
Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 12 months is below that.
Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking Union Medical College Hospital →